Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma

被引:11
作者
Li, Lei [3 ]
Chen, Xi [1 ]
Hao, Lu [2 ]
Chen, Qiuyan [2 ]
Liu, Haosheng [1 ]
Zhou, Qing [1 ]
机构
[1] Peoples Hosp Baoan Dist, Cent Lab, Shenzhen, Peoples R China
[2] Shenzhen Baoan Shiyan Peoples Hosp, Sci & Educ Dept, Shenzhen, Peoples R China
[3] Beihang Univ, Sch Biol Sci & Med Engn, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
CANCER-IMMUNOTHERAPY; MISSENSE MUTATION; CHECKPOINTS; PROLIFERATION; INHIBITION; EXPRESSION; SURVIVAL;
D O I
10.1042/BSR20201491
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Renal cell carcinoma (RCC) is one of most common cancers with gradually increasing inci-dence and high mortality. Chromogenic RCC (chRCC) is the third most common histological subtype of RCC, accounting for approximately 5-7% of RCC. In our study, the transcrip-tome expression profile data (n=89) of chRCC, corresponding clinical data (n=113) and the somatic mutation data (n=66) were obtained from the TCGA database. We first analyzed the mutation data of chRCC patients and divided chRCC patients into high and low tumor mutation burden (TMB) groups based on the median TMB. We found that high TMB was sig-nificantly associated with worse prognosis and could promote tumor metastasis and devel-opment. Moreover, four different immune-related genes (BIRC5, PDGFRL, INHBE, IL20RB) were also identified. We found that BIRC5 was significantly overexpressed in the high TMB group and correlated with worse prognosis. The results of univariate and multivariate COX analyses demonstrated that BIRC5 (hazard ratio (HR) = 2.094) may serve as a prognos-tic indicator for patients with chRCC with high TMB. In addition, we identified the possible functional pathways of BIRC5 through gene set enrichment analysis (GSEA) enrichment. A positive correlation was obtained between BIRC5 and the abundance of CD4(+) T cells. The results of our study revealed their correlation between the immune-related genes and clini-copathologic features as well as potential functional pathways as well as immune infiltrating cells, which may provide more data about the development of chRCC immunotherapy.
引用
收藏
页数:10
相关论文
共 56 条
[1]   Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients [J].
Ali, H. R. ;
Provenzano, E. ;
Dawson, S-J ;
Blows, F. M. ;
Liu, B. ;
Shah, M. ;
Earl, H. M. ;
Poole, C. J. ;
Hiller, L. ;
Dunn, J. A. ;
Bowden, S. J. ;
Twelves, C. ;
Bartlett, J. M. S. ;
Mahmoud, S. M. A. ;
Rakha, E. ;
Ellis, I. O. ;
Liu, S. ;
Gao, D. ;
Nielsen, T. O. ;
Pharoah, P. D. P. ;
Caldas, C. .
ANNALS OF ONCOLOGY, 2014, 25 (08) :1536-1543
[2]  
[Anonymous], 2017, Cancer Discov, V7, pOF5, DOI 10.1158/2159-8290.CD-NB2017-133
[3]   Human Renal Normal, Tumoral, and Cancer Stem Cells Express Membrane-Bound Interleukin-15 Isoforms Displaying Different Functions [J].
Azzi, Sandy ;
Gallerne, Cindy ;
Romei, Cristina ;
Le Coz, Vincent ;
Gangemi, Rosaria ;
Khawam, Krystel ;
Devocelle, Aurore ;
Gu, Yanhong ;
Bruno, Stefania ;
Ferrini, Silvano ;
Chouaib, Salem ;
Eid, Pierre ;
Azzarone, Bruno ;
Giron-Michel, Julien .
NEOPLASIA, 2015, 17 (06) :509-517
[4]   At the intersection of DNA damage and immune responses [J].
Bednarski, Jeffrey J. ;
Sleckman, Barry P. .
NATURE REVIEWS IMMUNOLOGY, 2019, 19 (04) :231-242
[5]   The Role of Circulating Tumor DNA in Renal Cell Carcinoma [J].
Bergerot, Paulo G. ;
Hahn, Andrew W. ;
Bergerot, Cristiane Decat ;
Jones, Jeremy ;
Pal, Sumanta Kumar .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (02)
[6]   Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer [J].
Boumber, Yanis .
JOURNAL OF THORACIC DISEASE, 2018, 10 (08) :4689-4693
[7]   Genomic Approaches to Understanding Response and Resistance to Immunotherapy [J].
Braun, David A. ;
Burke, Kelly P. ;
Van Allen, Eliezer M. .
CLINICAL CANCER RESEARCH, 2016, 22 (23) :5642-5650
[8]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[9]   OCT4 increases BIRC5 and CCND1 expression and promotes cancer progression in hepatocellular carcinoma [J].
Cao, Lu ;
Li, Chunguang ;
Shen, Shuwen ;
Yan, Yan ;
Ji, Weidan ;
Wang, Jinghan ;
Qian, Haihua ;
Jiang, Xiaoqing ;
Li, Zhigang ;
Wu, Mengchao ;
Zhang, Ying ;
Su, Changqing .
BMC CANCER, 2013, 13
[10]   Prognostic Value of BIRC5 in Lung Adenocarcinoma Lacking EGFR, KRAS, and ALK Mutations by Integrated Bioinformatics Analysis [J].
Cao, Yajuan ;
Zhu, Weikang ;
Chen, Wanqing ;
Wu, Jianchun ;
Hou, Guozhen ;
Li, Yan .
DISEASE MARKERS, 2019, 2019